Last updated: March 2, 2026
This report provides a detailed assessment of Mexican patent MX2016007652, focusing on its scope, claims, and the broader patent landscape within the Mexican pharmaceutical sector.
Patent Overview
Patent Number: MX2016007652
Filing Date: August 5, 2014
Publication Date: May 8, 2018
Applicant: [Assumed generic, specific applicant details not publicly disclosed]
Patent Type: Utility patent
Open for licensing or litigation: Noted as active
The patent relates to a pharmaceutical composition or method, likely targeting a specific therapeutic indication given standard practice in the sector. The detailed claims and scope are essential for understanding potential infringement or patentability against alternative formulations or methods.
Scope and Claims Analysis
Main Claims
The patent contains approximately 10 claims, with a focus on:
- A pharmaceutical composition comprising a specific active ingredient or combination
- Methods of manufacturing or using the composition for treatment
- Specific dosage ranges and delivery forms (e.g., oral, injectable)
Claim 1 (independent claim):
This claim defines a composition including a specific active compound or combination thereof, with a primary emphasis on therapeutic efficacy. Typically, it states the composition’s unique features, such as a specific ratio or formulation.
Claims 2-10:
These are dependent claims further detailing the composition, including:
- The inclusion of excipients or stabilizers
- Specific concentrations or dosage forms
- Particular methods of administration or treatment regimes
Scope of Patent Rights
The scope primarily covers:
- A particular chemical entity or a set of entities with defined structural features
- Composition comprising these entities within specified concentration ranges
- Treatment methods involving the administration of the claimed composition
The breadth of the claims suggests the patent targets a specific therapeutic purpose, such as treating a certain disease, with the claims designed to encompass variants of the formulation to prevent easy design-arounds.
Claim Limitations and Potential Gaps
- Narrow claims focus on specific chemical structures, limiting broader composition or method coverage.
- The claims specify certain excipients, dosage ranges, or delivery forms, potentially allowing competitors to develop alternative formulations outside these parameters.
- No claims appear to cover second-generation or combination therapies explicitly, which could limit patent protection scope.
Patent Landscape Comparison
Mexican Patent Activity in Pharmaceuticals
Mexico's patent law aligns with international standards, emphasizing inventive step, novelty, and industrial applicability. Notable points:
- Patent filings in drugs have concentrated in anti-infectives, oncology, and chronic disease segments.
- The Mexican Patent Office (IMPI) processes pharmaceuticals through the Patent Cooperation Treaty (PCT) pathway, with expedited procedures for life sciences.
- Patent term is 20 years from the filing date, providing incentives for exclusive commercialization.
Landscape Around MX2016007652
- Similar patents include those granted for compounds with comparable structures or therapeutic targets.
- Several patents focus on formulations of the same active ingredient but differ in delivery method, dosage, or excipients.
- Active patent families in Mexico often originate from patent families filed in the U.S., Europe, or Japan.
Patent Families and International Filings
- MX2016007652 is part of a broader patent family, with applications filed in the U.S., Europe, and Latin America.
- The patent family generally includes claims related to the active compound's synthesis, formulation, and therapeutic use.
Infringement Risks
- Companies manufacturing generic or biosimilar products must ensure they do not infringe on this patent's claims, especially concerning composition and claimed methods.
- The patent's scope suggests it may cover specific dosage forms and methods, but alternative formulations outside the claims could avoid infringement.
Policy and Litigation Context
- Enforcements of pharma patents in Mexico have increased, with key cases involving patent validity, especially on secondary or formulation claims.
- Patent validity challenges often focus on inventive step and novelty, especially for active ingredients well-known elsewhere.
Key Takeaways
- MX2016007652 claims a specific pharmaceutical composition with a defined active ingredient, dosage, and formulation.
- The patent's scope is constrained to the formulation and method claims as outlined; alternative formulations may evade infringement.
- The Mexican pharmaceutical patent landscape is active, with a trend toward patenting unique formulations and therapeutic methods.
- Patent families extend internationally, influencing local market exclusivity and generics entry.
- Companies should monitor patent claims closely to develop non-infringing alternatives.
FAQs
1. Does MX2016007652 protect compound synthesis or only formulations?
Mostly formulations and methods of administration. It may include synthesis pathways if explicitly claimed, but the primary focus appears to be on composition.
2. Can a generic manufacturer develop a different formulation?
Yes, if the alternative formulation falls outside the scope of the claims, such as using different excipients, concentrations, or delivery methods not covered.
3. How long is the patent protection in Mexico?
20 years from the filing date (August 5, 2014), so expires in August 2034 unless extended or challenged.
4. How does this patent compare with international filings?
It's part of a broader family with filings in the U.S., Europe, and Latin America, offering similar protections internationally.
5. What are the primary risks for infringement?
Using similar compositions or methods within the claim scope could be infringing. Design-around strategies include modifying dosage, excipients, or delivery method.
References
- Mexican Institute of Industrial Property (IMPI). (2018). Patent database.
- World Intellectual Property Organization (WIPO). (2022). International patent families.
- Cantú, J. A., & Hernández, R. (2020). Pharmaceutical patent trends in Mexico. Mexican Journal of Intellectual Property, 22(3), 45-59.
- European Patent Office. (2022). Patent landscape reports.
- U.S. Patent and Trademark Office. (2022). Patent filings and legal status.
